NovaBay Pharmaceuticals Statistics
Share Statistics
NovaBay Pharmaceuticals has 5.82M
shares outstanding. The number of shares has increased by 438.09%
in one year.
| Shares Outstanding | 5.82M |
| Shares Change (YoY) | 438.09% |
| Shares Change (QoQ) | 19.05% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,554 |
| FTD / Avg. Volume | 2.56% |
Short Selling Information
The latest short interest is 96.25K, so 1.65% of the outstanding
shares have been sold short.
| Short Interest | 96.25K |
| Short % of Shares Out | 1.65% |
| Short % of Float | 1.85% |
| Short Ratio (days to cover) | 2.85 |
Valuation Ratios
The PE ratio is -0.28 and the forward
PE ratio is -1.58.
NovaBay Pharmaceuticals's PEG ratio is
0.
| PE Ratio | -0.28 |
| Forward PE | -1.58 |
| PS Ratio | 0.21 |
| Forward PS | 0.2 |
| PB Ratio | -15.82 |
| P/FCF Ratio | -0.39 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for NovaBay Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.68,
with a Debt / Equity ratio of -12.96.
| Current Ratio | 0.68 |
| Quick Ratio | 0.41 |
| Debt / Equity | -12.96 |
| Debt / EBITDA | -0.28 |
| Debt / FCF | -0.32 |
| Interest Coverage | -6.46 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $752,384.62 |
| Profits Per Employee | $-555,615.38 |
| Employee Count | 13 |
| Asset Turnover | 2.86 |
| Inventory Turnover | 4.31 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -86.19% in the
last 52 weeks. The beta is 0.42, so NovaBay Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.42 |
| 52-Week Price Change | -86.19% |
| 50-Day Moving Average | 0.58 |
| 200-Day Moving Average | 0.6 |
| Relative Strength Index (RSI) | 50.5 |
| Average Volume (20 Days) | 60,752 |
Income Statement
In the last 12 months, NovaBay Pharmaceuticals had revenue of 9.78M
and earned -7.22M
in profits. Earnings per share was -2.53.
| Revenue | 9.78M |
| Gross Profit | 6.48M |
| Operating Income | -5.84M |
| Net Income | -7.22M |
| EBITDA | -5.92M |
| EBIT | -6.31M |
| Earnings Per Share (EPS) | -2.53 |
Full Income StatementBalance Sheet
The company has 430K in cash and 1.67M in
debt, giving a net cash position of -1.24M.
| Cash & Cash Equivalents | 430K |
| Total Debt | 1.67M |
| Net Cash | -1.24M |
| Retained Earnings | -183.46M |
| Total Assets | 3.42M |
| Working Capital | -908K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -5.18M
and capital expenditures -6K, giving a free cash flow of -5.19M.
| Operating Cash Flow | -5.18M |
| Capital Expenditures | -6K |
| Free Cash Flow | -5.19M |
| FCF Per Share | -1.53 |
Full Cash Flow StatementMargins
Gross margin is 66.26%, with operating and profit margins of -59.7% and -73.85%.
| Gross Margin | 66.26% |
| Operating Margin | -59.7% |
| Pretax Margin | -73.71% |
| Profit Margin | -73.85% |
| EBITDA Margin | -60.58% |
| EBIT Margin | -59.7% |
| FCF Margin | -53.05% |
